[
  {
    "ts": null,
    "headline": "ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial",
    "summary": "MSD confirmed a recommended dose has been identified as the Phase III portion continues enrolment.",
    "url": "https://finnhub.io/api/news?id=89f2bcd7095a400ab36b6d350c4d449bcf36a7df4c426207b9a573c902b474f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748623416,
      "headline": "ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial",
      "id": 134906495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MSD confirmed a recommended dose has been identified as the Phase III portion continues enrolment.",
      "url": "https://finnhub.io/api/news?id=89f2bcd7095a400ab36b6d350c4d449bcf36a7df4c426207b9a573c902b474f8"
    }
  },
  {
    "ts": null,
    "headline": "Walmart, Amgen share gains contribute to Dow's 100-point jump",
    "summary": "Walmart, Amgen share gains contribute to Dow's 100-point jump",
    "url": "https://finnhub.io/api/news?id=db9284df799e3c0bf7268912c87b1357554d8dfda3bfc07d844a888d02940ff0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618280,
      "headline": "Walmart, Amgen share gains contribute to Dow's 100-point jump",
      "id": 134940272,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Walmart, Amgen share gains contribute to Dow's 100-point jump",
      "url": "https://finnhub.io/api/news?id=db9284df799e3c0bf7268912c87b1357554d8dfda3bfc07d844a888d02940ff0"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The Dow Chase June's \"Safer\" Buy -- Verizon",
    "summary": "My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, June 2025 edition. Read the full report and list of stock picks here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=44d976ba7db3be633e540e5f641994b1f0a1556bead691a6bf5497cf05703d46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748617632,
      "headline": "Dogs Of The Dow Chase June's \"Safer\" Buy -- Verizon",
      "id": 134907299,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953651766/image_953651766.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, June 2025 edition. Read the full report and list of stock picks here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=44d976ba7db3be633e540e5f641994b1f0a1556bead691a6bf5497cf05703d46"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure",
    "summary": "Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.",
    "url": "https://finnhub.io/api/news?id=b4b269f0e505977546ccd20e6845f4ddd13f42c31ed90540ab20de45e62c3ad3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748611339,
      "headline": "Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure",
      "id": 134899098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.",
      "url": "https://finnhub.io/api/news?id=b4b269f0e505977546ccd20e6845f4ddd13f42c31ed90540ab20de45e62c3ad3"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations",
    "summary": "RAHWAY, N.J., May 30, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and in combination with other therapies in certain patients with KRAS G12C-mutant solid tumors, including advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). In patients with advanced KR",
    "url": "https://finnhub.io/api/news?id=5951963ae0a59d68a5626854f224e3b5172385d11fa464ca555e4462af31c3f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748606700,
      "headline": "Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations",
      "id": 134899100,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., May 30, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and in combination with other therapies in certain patients with KRAS G12C-mutant solid tumors, including advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). In patients with advanced KR",
      "url": "https://finnhub.io/api/news?id=5951963ae0a59d68a5626854f224e3b5172385d11fa464ca555e4462af31c3f4"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial",
    "summary": "RAHWAY, N.J., May 30, 2025--Zilovertamab Vedotin Plus SOC Showed Promising Antitumor Activity, Complete Response Rate, in Relapsed/Refractory DLBCL in waveLINE-003 Trial",
    "url": "https://finnhub.io/api/news?id=bf459d7fbcbb1e7da690b4043492c2aababd46a4de1feb8782532467a1bc3f81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748606400,
      "headline": "Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial",
      "id": 134899101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., May 30, 2025--Zilovertamab Vedotin Plus SOC Showed Promising Antitumor Activity, Complete Response Rate, in Relapsed/Refractory DLBCL in waveLINE-003 Trial",
      "url": "https://finnhub.io/api/news?id=bf459d7fbcbb1e7da690b4043492c2aababd46a4de1feb8782532467a1bc3f81"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
    "summary": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=b711ffff6bce49ff9d5022585a2f181130d7472e23b9296d94389bf9ea6cd4ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748604900,
      "headline": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
      "id": 134904305,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b711ffff6bce49ff9d5022585a2f181130d7472e23b9296d94389bf9ea6cd4ef"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Investigational Zilovertamab Vedotin at 1.75 mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients with Relapsed/Refractory DLBCL in Phase 2 Portion of Waveline-003 Trial",
    "summary": "Merck announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and...",
    "url": "https://finnhub.io/api/news?id=a4329f32ca2830fe6f5c347991ea09024e61becda10f9ae0bb5255f21f040d7d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748598647,
      "headline": "Merck's Investigational Zilovertamab Vedotin at 1.75 mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients with Relapsed/Refractory DLBCL in Phase 2 Portion of Waveline-003 Trial",
      "id": 134898315,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and...",
      "url": "https://finnhub.io/api/news?id=a4329f32ca2830fe6f5c347991ea09024e61becda10f9ae0bb5255f21f040d7d"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients with Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations",
    "summary": "Merck & Co., Inc. announced safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor,...",
    "url": "https://finnhub.io/api/news?id=738626cf3d854e8957bebd9e9572240c222888923c4eae92e98d475e5d917854",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748598641,
      "headline": "Merck & Co., Inc. Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients with Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations",
      "id": 134898317,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co., Inc. announced safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor,...",
      "url": "https://finnhub.io/api/news?id=738626cf3d854e8957bebd9e9572240c222888923c4eae92e98d475e5d917854"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor",
    "summary": "Merck & Co Inc: * MERCK ANNOUNCES MK-1084, AN INVESTIGATIONAL KRAS G12CINHIBITOR,SHOWS ANTITUMOR ACTIVITY IN PHASE 1 TRIAL OF PATIENTS WITHADVANCED COLORECTAL CANCER AND NON-SMALL...",
    "url": "https://finnhub.io/api/news?id=95eeb6959e4cd84271a3bd8fa5915f535fd8d0a2ce5c44168d191a92c9de3f7c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748595192,
      "headline": "Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor",
      "id": 134894638,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK ANNOUNCES MK-1084, AN INVESTIGATIONAL KRAS G12CINHIBITOR,SHOWS ANTITUMOR ACTIVITY IN PHASE 1 TRIAL OF PATIENTS WITHADVANCED COLORECTAL CANCER AND NON-SMALL...",
      "url": "https://finnhub.io/api/news?id=95eeb6959e4cd84271a3bd8fa5915f535fd8d0a2ce5c44168d191a92c9de3f7c"
    }
  },
  {
    "ts": null,
    "headline": "Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity",
    "summary": "Merck & Co Inc: * MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KGDOSEPLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY,INCLUDING COMPLETE RESPONSE RATE, IN...",
    "url": "https://finnhub.io/api/news?id=f380cd65a8df33dbc34dfa15f62169a34f1780bb6ef9c704e626b55b96a6f509",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748592450,
      "headline": "Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity",
      "id": 134894045,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KGDOSEPLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY,INCLUDING COMPLETE RESPONSE RATE, IN...",
      "url": "https://finnhub.io/api/news?id=f380cd65a8df33dbc34dfa15f62169a34f1780bb6ef9c704e626b55b96a6f509"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of",
    "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
    "url": "https://finnhub.io/api/news?id=db1fe2c6f88697a332d2469c8f942878cef3f6a786240d6357796ad5d740445a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748579625,
      "headline": "2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of",
      "id": 134899104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
      "url": "https://finnhub.io/api/news?id=db1fe2c6f88697a332d2469c8f942878cef3f6a786240d6357796ad5d740445a"
    }
  }
]